Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.

导出 OA

翻译打印收藏纠错

第一作者： Robert,Wesolowski

第一单位： Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Dr 1250 Lincoln Tower Columbus, OH, 43210, USA.

作者： Robert,Wesolowski ^[1] ; Neelesh,Sharma ^[2] ; Laura,Reebel ^[3] ; Mary Beth,Rodal ^[2] ; Alexandra,Peck ^[4] ; Brian L,West ^[5] ; Adhirai,Marimuthu ^[5] ; Paul,Severson ^[5] ; David A,Karlin ^[5] ; Afshin,Dowlati ^[2] ; Mai H,Le ^[5] ; Lisa M,Coussens ^[6] ; Hope S,Rugo ^[4]

作者单位： Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1800 Cannon Dr 1250 Lincoln Tower Columbus, OH, 43210, USA. ^[1] Case Western Reserve University, Cleveland, OH, USA. ^[2] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. ^[3] University of California San Francisco, CA, USA. ^[4] Plexxikon Inc. Berkeley, CA, USA. ^[5] Oregon Health and Sciences University, Portland, OR, USA. ^[6]

关键词 advanced solid tumors colony stimulating factor receptor 1 inhibitor paclitaxel phase?I trials tumor associated macrophages

DOI 10.1177/1758835919854238

PMID 31258629

发布时间 2022-04-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览8

Therapeutic advances in medical oncology

2019年11卷

1758835919854238页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

检索历史清除